VivoSeq
Other

Polyuria

13

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Polyuria is an emerging landscape with 13 programs across 6 companies. The most active players are Astellas, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Pfizer. 8 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

40/100

Pipeline Velocity

0/100

Mech. Concentration

22/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

2 programs

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedAbbVie logo

AbbVie

1 program

ApprovedFerring logo

Ferring

3 programs

ApprovedM

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

9

clinical trials

Completed8 · 89%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Polyuria Associated With Dexmedetomidine in Operating Room
Not yet recruiting·HHospital Privado de Comunidad de Mar del Plata·N/A·NCT06535386·150 enrolled
Desmopressin Melt Therapy in Patients With Nocturnal Polyuria: a Pharmacokinetic/Dynamic Study
Completed·UUniversity Hospital, Ghent·Phase 4·NCT01435083·50 enrolled
Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Completed·SSanwa Kagaku Kenkyusho Co., Ltd.·Phase 2·NCT03116191·125 enrolled
A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults
Completed·Ferring logoFerring·Phase 2·NCT03201419·302 enrolled
Desmopressin Melt Therapy in Nocturnal Polyuria Patients: Pharmacodynamic Study
Completed·UUniversity Hospital, Ghent·Phase 4·NCT01439997·5 enrolled
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects
Completed·Ferring logoFerring·Phase 3·NCT02905682·190 enrolled
Desmopressin in the Treatment of Mixed Nocturia With Nocturnal Polyuria and Low Nocturnal Bladder Capacity
Completed·SSamsung Medical Center·Phase 4·NCT00902655·103 enrolled
Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects
Completed·Ferring logoFerring·Phase 3·NCT03051009·503 enrolled
Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
Completed·Ferring logoFerring·Phase 3·NCT02904759·342 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)